Cargando…

Prophylactic oophorectomy and aromatase inhibitors for premenopausal deep angiomyxoma: A case report and literature review

Deep angiomyxoma is a rare, infiltrative, hormone-dependent, benign-mesenchymal neoplasm that occurs in the deep soft tissues of the perineal regions. In total, 33% females with newly diagnosed deep angiomyxoma will typically relapse within 5 years after the standard treatment of radical resection....

Descripción completa

Detalles Bibliográficos
Autores principales: Tonai, Nobutomo, Nasu, Kaei, Yano, Mitsutake, Sato, Miho, Kai, Kentaro, Nishida, Masakazu, Kawano, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748652/
https://www.ncbi.nlm.nih.gov/pubmed/36561620
http://dx.doi.org/10.3892/etm.2022.11702
_version_ 1784849869074071552
author Tonai, Nobutomo
Nasu, Kaei
Yano, Mitsutake
Sato, Miho
Kai, Kentaro
Nishida, Masakazu
Kawano, Yasushi
author_facet Tonai, Nobutomo
Nasu, Kaei
Yano, Mitsutake
Sato, Miho
Kai, Kentaro
Nishida, Masakazu
Kawano, Yasushi
author_sort Tonai, Nobutomo
collection PubMed
description Deep angiomyxoma is a rare, infiltrative, hormone-dependent, benign-mesenchymal neoplasm that occurs in the deep soft tissues of the perineal regions. In total, 33% females with newly diagnosed deep angiomyxoma will typically relapse within 5 years after the standard treatment of radical resection. Postoperative hormone therapy is frequently administered to prevent recurrence, but the role of prophylactic oophorectomy in premenopausal women remain to be fully elucidated. In the present report, a 42-year-old Japanese woman was referred for a refractory Bartholin's cyst that is 14 cm in diameter. Based on the results of imaging (unenhanced CT and MRI) and histopathology, deep angiomyxoma was suspected, but no definitive diagnosis was possible. Tumor resection and bilateral salpingo-oophorectomy were performed before the postoperative diagnosis was confirmed to be deep angiomyxoma. The patient received an aromatase inhibitor (2.5 mg letrozole daily) as adjuvant hormonal therapy. There was no evidence of recurrence at the 1-year postoperative follow-up. In conclusion, prophylactic oophorectomy and postoperative adjuvant therapy with aromatase inhibitors may be a promising treatment option for deep angiomyxoma to optimize the outcome of surgical treatment. Long-term follow-up is required to monitor for the late and/or local recurrence of deep angiomyxoma and possible adverse effects of adjuvant hormonal therapy.
format Online
Article
Text
id pubmed-9748652
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-97486522022-12-21 Prophylactic oophorectomy and aromatase inhibitors for premenopausal deep angiomyxoma: A case report and literature review Tonai, Nobutomo Nasu, Kaei Yano, Mitsutake Sato, Miho Kai, Kentaro Nishida, Masakazu Kawano, Yasushi Exp Ther Med Case Report Deep angiomyxoma is a rare, infiltrative, hormone-dependent, benign-mesenchymal neoplasm that occurs in the deep soft tissues of the perineal regions. In total, 33% females with newly diagnosed deep angiomyxoma will typically relapse within 5 years after the standard treatment of radical resection. Postoperative hormone therapy is frequently administered to prevent recurrence, but the role of prophylactic oophorectomy in premenopausal women remain to be fully elucidated. In the present report, a 42-year-old Japanese woman was referred for a refractory Bartholin's cyst that is 14 cm in diameter. Based on the results of imaging (unenhanced CT and MRI) and histopathology, deep angiomyxoma was suspected, but no definitive diagnosis was possible. Tumor resection and bilateral salpingo-oophorectomy were performed before the postoperative diagnosis was confirmed to be deep angiomyxoma. The patient received an aromatase inhibitor (2.5 mg letrozole daily) as adjuvant hormonal therapy. There was no evidence of recurrence at the 1-year postoperative follow-up. In conclusion, prophylactic oophorectomy and postoperative adjuvant therapy with aromatase inhibitors may be a promising treatment option for deep angiomyxoma to optimize the outcome of surgical treatment. Long-term follow-up is required to monitor for the late and/or local recurrence of deep angiomyxoma and possible adverse effects of adjuvant hormonal therapy. D.A. Spandidos 2022-11-16 /pmc/articles/PMC9748652/ /pubmed/36561620 http://dx.doi.org/10.3892/etm.2022.11702 Text en Copyright: © Tonai et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Case Report
Tonai, Nobutomo
Nasu, Kaei
Yano, Mitsutake
Sato, Miho
Kai, Kentaro
Nishida, Masakazu
Kawano, Yasushi
Prophylactic oophorectomy and aromatase inhibitors for premenopausal deep angiomyxoma: A case report and literature review
title Prophylactic oophorectomy and aromatase inhibitors for premenopausal deep angiomyxoma: A case report and literature review
title_full Prophylactic oophorectomy and aromatase inhibitors for premenopausal deep angiomyxoma: A case report and literature review
title_fullStr Prophylactic oophorectomy and aromatase inhibitors for premenopausal deep angiomyxoma: A case report and literature review
title_full_unstemmed Prophylactic oophorectomy and aromatase inhibitors for premenopausal deep angiomyxoma: A case report and literature review
title_short Prophylactic oophorectomy and aromatase inhibitors for premenopausal deep angiomyxoma: A case report and literature review
title_sort prophylactic oophorectomy and aromatase inhibitors for premenopausal deep angiomyxoma: a case report and literature review
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748652/
https://www.ncbi.nlm.nih.gov/pubmed/36561620
http://dx.doi.org/10.3892/etm.2022.11702
work_keys_str_mv AT tonainobutomo prophylacticoophorectomyandaromataseinhibitorsforpremenopausaldeepangiomyxomaacasereportandliteraturereview
AT nasukaei prophylacticoophorectomyandaromataseinhibitorsforpremenopausaldeepangiomyxomaacasereportandliteraturereview
AT yanomitsutake prophylacticoophorectomyandaromataseinhibitorsforpremenopausaldeepangiomyxomaacasereportandliteraturereview
AT satomiho prophylacticoophorectomyandaromataseinhibitorsforpremenopausaldeepangiomyxomaacasereportandliteraturereview
AT kaikentaro prophylacticoophorectomyandaromataseinhibitorsforpremenopausaldeepangiomyxomaacasereportandliteraturereview
AT nishidamasakazu prophylacticoophorectomyandaromataseinhibitorsforpremenopausaldeepangiomyxomaacasereportandliteraturereview
AT kawanoyasushi prophylacticoophorectomyandaromataseinhibitorsforpremenopausaldeepangiomyxomaacasereportandliteraturereview